BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBIO) is a clinical-stage biotechnology company focused on developing precision oncology therapies targeting cancers driven by RAS and PI3Kα, two of the most frequently mutated oncogenes in human cancer. The company's website is www.bridgebio.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What BridgeBio Oncology Therapeutics, Inc. does
In the company’s own words
BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBIO) is a clinical-stage biotechnology company focused on developing precision oncology therapies targeting cancers driven by RAS and PI3Kα, two of the most frequently mutated oncogenes in human cancer. The company's website is www.bridgebio.com.
The company operates through a pipeline of three orally bioavailable small molecule inhibitors designed to address large patient populations with metastatic cancers. BBO-8520 is a dual KRAS G12C ON/OFF inhibitor currently in Phase 1 development through the ONKORAS-101 trial for non-small cell lung cancer patients with KRAS G12C mutations, evaluated both as monotherapy and in combination with pembrolizumab. BBO-11818 represents a pan-KRAS ON/OFF inhibitor targeting KRAS G12D, G12V, and G12C mutations, with the KONQUER-101 Phase 1 study evaluating its safety and efficacy in heavily pretreated patients with KRAS mutant solid tumors. BBO-10203 is a RAS:PI3Kα Breaker designed to block RAS activation of PI3Kα while avoiding hyperglycemia and hyperinsulinemia side effects associated with traditional PI3Kα kinase inhibitors, currently being studied in the BREAKER-101 trial across HER2-positive breast cancer, hormone receptor-positive breast cancer, and KRAS mutant colorectal cancer.
BridgeBio Oncology Therapeutics was formed through a business combination between Helix Acquisition Corp. II and TheRas, Inc., which closed on August 11, 2025. The company employs a structure-based drug design approach to maximize target inhibition while maintaining favorable tolerability profiles. The company's strategy emphasizes developing its pipeline candidates both as monotherapies and in combination regimens, with particular focus on addressing resistance mechanisms in KRAS-driven tumors through dual pathway inhibition combining MAPK and PI3Kα-AKT pathway targeting. The company has disclosed preliminary clinical data from its three ongoing Phase 1 trials, demonstrating encouraging efficacy signals and differentiated safety profiles compared to existing therapies in these oncology spaces.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1869105
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns BridgeBio Oncology Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · BridgeBio Oncology Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do BridgeBio Oncology Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of BridgeBio Oncology Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in BridgeBio Oncology Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”